James Dennewill
Vermögen: 3 Mio $ am 31.08.2026
Vermögen: 3 Mio $ am 31.08.2026
James Dennewill is the Chief Operating Officer at SpyGlass Pharma, Inc. since 2021, with employment at the company starting in 2019.
Formerly, Mr. Dennewill was the Chief Operating Officer at Cianna Medical, Inc. Education includes an undergraduate degree from The California State University and an MBA from Yale School of Management.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 05.02.2026 | 96’022 ( 0.29% ) | 3 Mio $ | 31.08.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| SPYGLASS PHARMA, INC. | Geschäftsführer | 01.10.2021 |
| Unternehmen | Position | Ende |
|---|---|---|
Cianna Medical, Inc.
Cianna Medical, Inc. Medical SpecialtiesHealth Technology Manufactures and designs medical products for treatment of early-stage breast cancer in women | Geschäftsführer | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 4 |
|---|---|
The California State University
The California State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cianna Medical, Inc.
Cianna Medical, Inc. Medical SpecialtiesHealth Technology Manufactures and designs medical products for treatment of early-stage breast cancer in women | Health Technology |
Yale School of Management
Yale School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
SpyGlass Pharma Inc
SpyGlass Pharma Inc BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops IOL-mounted drug delivery platform for glaucoma patients | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen